Jonathan Allan - Dec 1, 2025 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
GENERAL COUNSEL & CORP SEC
Signature
/s/ Jonathan Allan
Stock symbol
STOK
Transactions as of
Dec 1, 2025
Transactions value $
-$138,268
Form type
4
Date filed
12/3/2025, 08:20 PM
Previous filing
Oct 7, 2025
Next filing
Dec 5, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Allan Jonathan GENERAL COUNSEL & CORP SEC C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD /s/ Jonathan Allan 2025-12-03 0001966716

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Options Exercise $0 +12.4K +104.45% $0.00 24.2K Dec 1, 2025 Direct
transaction STOK Common Stock Sale -$41.9K -1.42K -5.85% $29.56 22.8K Dec 2, 2025 Direct F1, F2
transaction STOK Common Stock Sale -$26.2K -868 -3.81% $30.14 21.9K Dec 2, 2025 Direct F1, F3
transaction STOK Common Stock Sale -$27.2K -898 -4.1% $30.34 21K Dec 3, 2025 Direct F1, F4
transaction STOK Common Stock Sale -$43K -1.39K -6.64% $30.85 19.6K Dec 3, 2025 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STOK Restricted Stock Units Options Exercise $0 -12.4K -100% $0.00 0 Dec 1, 2025 Common Stock 12.4K Direct F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.93 to $29.92 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.93 to $30.63 per share, inclusive.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.81 to $30.805 per share, inclusive.
F5 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.815 to $31.17 per share, inclusive.
F6 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F7 33,927 restricted stock units from this award vested on December 1, 2024 and 12,357 vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date.